TY - JOUR
T1 - Survey of the clinical practice pattern of using sentinel lymph node biopsy in patients with gynecological cancers in Japan
T2 - the Japan Society of Gynecologic Oncology study
AU - Togami, Shinichi
AU - Kobayashi, Hiroaki
AU - Niikura, Hitoshi
AU - Shimada, Muneaki
AU - Susumu, Nobuyuki
AU - Tanaka, Tomohito
AU - Terai, Yoshito
AU - Nagai, Tomoyuki
AU - Baba, Tsukasa
AU - Yahata, Hideaki
AU - Yamagami, Wataru
AU - Yamaguchi, Ken
AU - Yamashita, Tsuyoshi
AU - Yaegashi, Nobuo
AU - Katabuchi, Hidetaka
AU - Aoki, Daisuke
N1 - Funding Information:
We are grateful to the 40 facilities that responded with the data on sentinel lymph node biopsy. The 40 facilities are as follows: Aichi Cancer Center, Asahikawa Medical College, Cancer Institute Hospital, Chiba University, Dokkyo Medical University, Fukui University, Gifu Prefectural General Medical Center, Gunma Prefectural Cancer Center, Hokkaido Cancer Center, Hakodate Municipal Hospital. Jikei University, Jikei University Daisan Hospital, Juntendo University, Kagoshima University, Kameda Medical Center, Kansai Medical University, Keio University, Kindai University, Kitakyushu Municipal Medical Center, Kobe City Medical Center General Hospital, Koshigaya Municipal Hospital, Kurume University, Kyoundo Hospital, Kyushu University, Mie University, National Hospital Organization Kyushu Cancer Center, Osaka International Cancer Institute, Osaka Medical College, Osaka University, Shinshu University, Shin-yurigaoka General Hospital, Tazuke Kofukai Medical Research Institute Kitano Hospital, Teikyo University, Tohoku University, University of Occupational and Environmental Health, Toyama Prefectural Central Hospital, Toyohashi Municipal Hospital, Yamagata University, Yokohama Municipal Citizen's Hospital.
Publisher Copyright:
© 2021, Japan Society of Clinical Oncology.
PY - 2021/5
Y1 - 2021/5
N2 - Background: Sentinel lymph node (SN) biopsy is essential for evaluating survival and minimal treatment-related morbidity associated with cervical, endometrial, and vulvar cancer in Japan. As such, our aim in this study was to evaluate the current practice pattern of using SN biopsy for cervical, endometrial, and vulvar cancer in Japan. Methods: We deployed a 47-question survey on the use of SN biopsy for gynecological cancers to 216 gynecological oncology training facilities. The survey included information on the use of SN biopsy for uterine (cervical and endometrial) and vulvar cancers; details on the type, timing, and concentration of tracers used; surgical approach used for SN biopsy; method of biopsy and pathological examination; and facilities’ experience with clinical research on SN biopsy. Results: The response rate was 84% (181/216), with 40 facilities (22%) having experience in SN biopsy for gynecological cancers, 34 (85%) for uterine cancers, and 15 (37%) for vulvar cancers. Radioisotope, indocyanine green (ICG), and blue dyes were available for the detection of uterine cancers in 21 (52%), 25 (62%), and 19 (48%) facilities and for vulvar cancers in 9 (22%), 3 (7%), and 11 (27%) facilities, respectively. Thirty-four facilities (85%) used intraoperative frozen section procedure for diagnosis when possible, with 24 (71%) of these facilities using 2-mm specimen cuts. Diagnosis included pathological examination (85%), immunostaining (57%), and one-step nucleic acid amplification (5%). Conclusion: Increasing research evidence, providing insurance coverage for radioisotope tracers, and increasing the availability of training are expected to increase the use of SN biopsy in Japan.
AB - Background: Sentinel lymph node (SN) biopsy is essential for evaluating survival and minimal treatment-related morbidity associated with cervical, endometrial, and vulvar cancer in Japan. As such, our aim in this study was to evaluate the current practice pattern of using SN biopsy for cervical, endometrial, and vulvar cancer in Japan. Methods: We deployed a 47-question survey on the use of SN biopsy for gynecological cancers to 216 gynecological oncology training facilities. The survey included information on the use of SN biopsy for uterine (cervical and endometrial) and vulvar cancers; details on the type, timing, and concentration of tracers used; surgical approach used for SN biopsy; method of biopsy and pathological examination; and facilities’ experience with clinical research on SN biopsy. Results: The response rate was 84% (181/216), with 40 facilities (22%) having experience in SN biopsy for gynecological cancers, 34 (85%) for uterine cancers, and 15 (37%) for vulvar cancers. Radioisotope, indocyanine green (ICG), and blue dyes were available for the detection of uterine cancers in 21 (52%), 25 (62%), and 19 (48%) facilities and for vulvar cancers in 9 (22%), 3 (7%), and 11 (27%) facilities, respectively. Thirty-four facilities (85%) used intraoperative frozen section procedure for diagnosis when possible, with 24 (71%) of these facilities using 2-mm specimen cuts. Diagnosis included pathological examination (85%), immunostaining (57%), and one-step nucleic acid amplification (5%). Conclusion: Increasing research evidence, providing insurance coverage for radioisotope tracers, and increasing the availability of training are expected to increase the use of SN biopsy in Japan.
KW - Cervical cancer
KW - Endometrial cancer
KW - Sentinel lymph node biopsy
KW - Survey
KW - Vulvar cancer
UR - http://www.scopus.com/inward/record.url?scp=85103300586&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103300586&partnerID=8YFLogxK
U2 - 10.1007/s10147-021-01862-7
DO - 10.1007/s10147-021-01862-7
M3 - Article
C2 - 33768450
AN - SCOPUS:85103300586
SN - 1341-9625
VL - 26
SP - 971
EP - 979
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 5
ER -